{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:07:39Z","timestamp":1791338859921,"version":"4.3.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"MSD Ltd","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00520-018-4443-3","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:26:43Z","timestamp":1535999203000},"page":"1845-1852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy"],"prefix":"10.1007","volume":"27","author":[{"given":"David","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-5169","authenticated-orcid":false,"given":"Haryana M.","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lomax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Marthick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"issue":"26","key":"4443_CR1","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long G, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 investigators (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532","journal-title":"N Engl J Med"},{"key":"4443_CR2","doi-asserted-by":"publisher","unstructured":"Larkin J, Minor D, D\u2019Angelo S et al (2017) Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in checkMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/JCO2016.71.8023","DOI":"10.1200\/JCO2016.71.8023"},{"issue":"17","key":"4443_CR3","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889\u2013U1848","journal-title":"J Clin Oncol"},{"issue":"6","key":"4443_CR4","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/bjd.14306","volume":"173","author":"PK Curl","year":"2015","unstructured":"Curl PK (2015) Navigating uncertainty: a valuable cost-effectiveness analysis in the rapidly changing field of metastatic melanoma treatment. Br J Dermatol 173(6):1365\u20131366","journal-title":"Br J Dermatol"},{"issue":"11","key":"4443_CR5","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/pon.3813","volume":"24","author":"LB Hope-Stone","year":"2015","unstructured":"Hope-Stone LB, Stephen L, Heimann H, Damato B, Salmon P (2015) How do patients with uveal melanoma experience and manage uncertainty? A qualitative study. Psycho-Oncology 24(11):1485\u20131491","journal-title":"Psycho-Oncology"},{"issue":"1","key":"4443_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1472-684X-13-28","volume":"13","author":"M Karlsson","year":"2014","unstructured":"Karlsson M, Friberg F, Wallengren C, Ohlen J (2014) Meanings of existential uncertainty and certainty for people diagnosed with cancer and receiving palliative treatment: a life-world phenomenological study. BMC Palliative Care 13(1):28\u201328","journal-title":"BMC Palliative Care"},{"issue":"4","key":"4443_CR7","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/bmjspcare-2013-000482","volume":"5","author":"A Richardson","year":"2015","unstructured":"Richardson A, Wagland R, Foster R, Symons J, Davis C, Boyland L, Foster C, Addington-Hall J (2015) Uncertainty and anxiety in the cancer of unknown primary patient journey: a multiperspective qualitative study. BMJ Support Palliat Care 5(4):366\u2013372","journal-title":"BMJ Support Palliat Care"},{"issue":"4","key":"4443_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/bmjspcare-2012-000381","volume":"5","author":"E Lobb","year":"2015","unstructured":"Lobb E, Lacey J, Kearsley J, Liauw W, White L, Hosie A (2015) Living with advanced cancer and an uncertain disease trajectory: an emerging patient population in palliative care? BMJ Support Palliat Care. 5(4):352\u2013357","journal-title":"BMJ Support Palliat Care."},{"key":"4443_CR9","first-page":"147","volume":"13","author":"J Lacey","year":"2017","unstructured":"Lacey J, Lomax A, Marthick M et al (2017) A supportive care intervention for people with metastatic melanoma treated with immunotherapy: a pilot study assessing feasibility and perceived benefit. Asia-Pac J Clin Oncol 13:147\u2013148","journal-title":"Asia-Pac J Clin Oncol"},{"issue":"20","key":"4443_CR10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"Association WM","year":"2013","unstructured":"Association WM (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191\u20132194","journal-title":"JAMA"},{"key":"4443_CR11","volume-title":"Interpretative phenomenological analysis: theory, method and research","author":"JA Smith","year":"2009","unstructured":"Smith JA, Flowers P, Larkin M (2009) Interpretative phenomenological analysis: theory, method and research. Sage Publications Ltd, London"},{"issue":"5","key":"4443_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/1363459314554319","volume":"19","author":"C Balmer","year":"2015","unstructured":"Balmer C, Griffiths F, Dunn J (2015) A \u2018new normal\u2019: exploring the disruption of a poor prognostic cancer diagnosis using interviews and participant-produced photographs. Health 19(5):451\u2013472","journal-title":"Health"},{"issue":"8","key":"4443_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.12968\/bjcn.2015.20.8.411","volume":"20","author":"A Mendes","year":"2015","unstructured":"Mendes A (2015) Helping people living with cancer adjust to their \u2018new normal\u2019. Br J Community Nurs 20(8):411\u2013411","journal-title":"Br J Community Nurs"},{"key":"4443_CR14","doi-asserted-by":"crossref","unstructured":"Beach PR. Surviving after cancer: living the new normal. Vol 38. Pittsburgh: Oncology Nursing Soc; 2011:599\u2013599","DOI":"10.1188\/11.ONF.599-600"},{"key":"4443_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.socscimed.2016.06.039","volume":"163","author":"M Dean","year":"2016","unstructured":"Dean M (2016) \u201cIt\u2019s not if I get cancer, it\u2019s when I get cancer\u201d: BRCA-positive patients\u2019 (un)certain health experiences regarding hereditary breast and ovarian cancer risk. Soc Sci Med 163:21\u201327","journal-title":"Soc Sci Med"},{"issue":"2","key":"4443_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/scs.12250","volume":"30","author":"SL Drageset","year":"2016","unstructured":"Drageset SL, Christine T, Giske T, Underlid K (2016) Women\u2019s experiences of social support during the first year following primary breast cancer surgery. Scand J Caring Sci 30(2):340\u2013348","journal-title":"Scand J Caring Sci"},{"issue":"3","key":"4443_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1043659614550488","volume":"27","author":"F\u015eG Inan","year":"2016","unstructured":"Inan F\u015eG, Partlak N, \u00dcst\u00fcn B (2016) Experiences of newly diagnosed breast cancer patients in Turkey. J Transcult Nurs 27(3):262\u2013269","journal-title":"J Transcult Nurs"},{"issue":"1","key":"4443_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00520-009-0624-4","volume":"18","author":"SF Cayless","year":"2010","unstructured":"Cayless SF, Liz, Illingworth N, Hubbard G, Kearney N (2010) Men with prostate cancer over the first year of illness: their experiences as biographical disruption. Support Care Cancer 18(1):11\u201319","journal-title":"Support Care Cancer"},{"issue":"4","key":"4443_CR19","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11764-010-0136-8","volume":"4","author":"SS Simard","year":"2010","unstructured":"Simard SS, Jos\u00e9e, Ivers H (2010) Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. J Cancer Surviv 4(4):361\u2013371","journal-title":"J Cancer Surviv"},{"issue":"2","key":"4443_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/0269216316647610","volume":"31","author":"SN Etkind","year":"2017","unstructured":"Etkind SN, Bristowe K, Bailey K, Selman LE, Murtagh FEM (2017) How does uncertainty shape patient experience in advanced illness? A secondary analysis of qualitative data. Palliat Med 31(2):171\u2013180","journal-title":"Palliat Med"},{"issue":"8","key":"4443_CR21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1177\/1049732312448542","volume":"22","author":"J McLoone","year":"2012","unstructured":"McLoone J, Watts K, Menzies S, Meiser B, Butow P, Kasparian N (2012) When the risks are high: psychological adjustment among melanoma survivors at high risk of developing new primary disease. Qual Health Res 22(8):1102\u20131113","journal-title":"Qual Health Res"},{"issue":"8","key":"4443_CR22","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1007\/s00520-016-3272-5","volume":"24","author":"S Lebel","year":"2016","unstructured":"Lebel S, Ozakinci G, Humphris G, Mutsaers B, Thewes B, Prins J, Dinkel A, Butow P (2016) From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer 24(8):3265\u20133268","journal-title":"Support Care Cancer"},{"key":"4443_CR23","doi-asserted-by":"crossref","unstructured":"Simonelli LES, Scott D, Duffy NM (2016) Fear of cancer recurrence: a theoretical review and its relevance for clinical presentation and management: fear of recurrence. Psycho-Oncology","DOI":"10.1002\/pon.4168"},{"issue":"10","key":"4443_CR24","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1007\/s00520-016-3248-5","volume":"24","author":"B Mutsaers","year":"2016","unstructured":"Mutsaers B, Jones G, Rutkowski N, Tomei C, Leclair S, Caroline, Petricone-Westwood D, Simard S, Lebel S (2016) When fear of cancer recurrence becomes a clinical issue: a qualitative analysis of features associated with clinical fear of cancer recurrence. Support Care Cancer 24(10):4207\u20134218","journal-title":"Support Care Cancer"},{"key":"4443_CR25","first-page":"181","volume-title":"Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications","author":"KF Grossmann","year":"2015","unstructured":"Grossmann KF, Margolin K (2015) Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications, vol 7. SAGE Publications, London, pp 181\u2013191"},{"issue":"8","key":"4443_CR26","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(16)30017-1","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, Long GV (2016) Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. Lancet Oncol 17(8):1037\u20131039","journal-title":"Lancet Oncol"},{"issue":"4","key":"4443_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ejon.2014.03.015","volume":"18","author":"S Hajdarevic","year":"2014","unstructured":"Hajdarevic S, Rasmussen BH, Hornsten A (2014) You never know when your last day will come and your trip will be over--existential expressions from a melanoma diagnosis. Eur J Oncol Nurs 18(4):355\u2013361","journal-title":"Eur J Oncol Nurs"},{"issue":"7","key":"4443_CR28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/pon.3718","volume":"24","author":"VL Beesley","year":"2015","unstructured":"Beesley VL, Smithers BM, Khosrotehrani K, Khatun M, O\u2019Rourke P, Hughes MCB, Malt MK, Zonta MJ, Bayley GJ, Barbour AP, Brown LJ, D\u2019Arcy J, Allan CP, Green AC (2015) Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. Psycho-Oncology 24(7):763\u2013770","journal-title":"Psycho-Oncology"},{"key":"4443_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.socscimed.2016.01.011","volume":"151","author":"D Trusson","year":"2016","unstructured":"Trusson D, Pilnick A, Roy S (2016) A new normal?: Women\u2019s experiences of biographical disruption and liminality following treatment for early stage breast cancer. Soc Sci Med 151:121\u2013129","journal-title":"Soc Sci Med"},{"issue":"4","key":"4443_CR30","first-page":"225","volume":"20","author":"MH Mishel","year":"1988","unstructured":"Mishel MH (1988) Uncertainty in illness. Image 20(4):225\u2013232","journal-title":"Image"},{"key":"4443_CR31","first-page":"2155","volume":"22","author":"E Blows","year":"2013","unstructured":"Blows E, Seymour J, Cox K (2013) Liminality as a framework for understanding experiences of long-term cancer survivorship. Psycho-Oncology 22:2155\u20132164","journal-title":"Psycho-Oncology"},{"issue":"10","key":"4443_CR32","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0277-9536(98)00248-2","volume":"47","author":"M Little","year":"1998","unstructured":"Little M, Jordens C, Paul K, Montgomery K, Philipson B (1998) Liminality: a major category of the experience of cancer illness. Soc Sci Med 47(10):1485\u20131494","journal-title":"Soc Sci Med"},{"key":"4443_CR33","volume-title":"The rites of passage","author":"AV Gennep","year":"1960","unstructured":"Gennep AV (1960) The rites of passage. Routledge & Kegan Paul, London"},{"key":"4443_CR34","volume-title":"The forest of symbols: aspects of Ndembu ritual","author":"VW Turner","year":"1967","unstructured":"Turner VW (1967) The forest of symbols: aspects of Ndembu ritual. Cornell University Press, Ithaca"},{"key":"4443_CR35","unstructured":"Turner VW (1969) The ritual process: structure and anti-structure. Vol 01\/1969. MLA International Bibliography"},{"key":"4443_CR36","doi-asserted-by":"crossref","unstructured":"Koutri I, Avdi E (2016) The suspended self: liminality in breast cancer narratives and implications for counselling. 5(1):78\u201396","DOI":"10.5964\/ejcop.v5i1.92"},{"issue":"4","key":"4443_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0539018406069584","volume":"45","author":"M Crouch","year":"2006","unstructured":"Crouch M, McKenzie H (2006) The logic of small samples in interview-based qualitative research. Soc Sci Inf 45(4):483\u2013499","journal-title":"Soc Sci Inf"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4443-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:11:12Z","timestamp":1567537872000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4443-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4443"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4443-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"26 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was granted by Sydney Local Health District \u2013 Concord zone Human Research Ethics Committee (HREC\/15\/CRGH\/265) in accordance with the Declaration of Helsinki","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Catriona McNeil received travel, conference, and accommodation support from MSD; has sat on MSD advisory boards; and has given talks for MSD and BMS (honoraria to Chris O\u2019Brien Lifehouse). Steven Kao received honoraria paid to his institution from Boeringher, Astrazeneca, Roche, Pfizer, BMS, and MSD. Steven Kao has had travel costs paid for by BMS, Roche, and AstraZeneca. Haryana Dhillon has received honoraria paid to her institution from MSD. Judith Lacey has received honoraria paid to her institution from TEVA and MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}